These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 20178475)

  • 21. Pharmacodynamics: relation to antimicrobial resistance.
    Rybak MJ
    Am J Infect Control; 2006 Jun; 34(5 Suppl 1):S38-45; discussion S64-73. PubMed ID: 16813981
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Predictors of bacterial resistance using in vitro dynamic models: area under the concentration-time curve related to either the minimum inhibitory or mutant prevention antibiotic concentration.
    Strukova EN; Portnoy YA; Zinner SH; Firsov AA
    J Antimicrob Chemother; 2016 Mar; 71(3):678-84. PubMed ID: 26626718
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of several fluoroquinolones and beta-lactams in terms of their capability to restrict the selection of fluoroquinolone-resistant Salmonella: in vitro models.
    Cebríán L; Rodríguez JC; Escribiano I; Royo SG
    APMIS; 2007 Dec; 115(12):1376-82. PubMed ID: 18184408
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dose-related selection of fluoroquinolone-resistant Escherichia coli.
    Olofsson SK; Marcusson LL; Strömbäck A; Hughes D; Cars O
    J Antimicrob Chemother; 2007 Oct; 60(4):795-801. PubMed ID: 17635875
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Selection of linezolid-resistant Enterococcus faecium in an in vitro dynamic model: protective effect of doxycycline.
    Zinner SH; Gilbert D; Lubenko IY; Greer K; Firsov AA
    J Antimicrob Chemother; 2008 Mar; 61(3):629-35. PubMed ID: 18245198
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Interpreting culture and susceptibility data in critical care: perks and pitfalls.
    Boothe DM
    J Vet Emerg Crit Care (San Antonio); 2010 Feb; 20(1):110-31. PubMed ID: 20230440
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mutant prevention concentration of ciprofloxacin and enrofloxacin against Escherichia coli, Salmonella Typhimurium and Pseudomonas aeruginosa.
    Pasquali F; Manfreda G
    Vet Microbiol; 2007 Jan; 119(2-4):304-10. PubMed ID: 16987619
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Restricting the selection of antibiotic-resistant mutants: a general strategy derived from fluoroquinolone studies.
    Zhao X; Drlica K
    Clin Infect Dis; 2001 Sep; 33 Suppl 3():S147-56. PubMed ID: 11524712
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Predicting bacterial resistance using the time inside the mutant selection window: possibilities and limitations.
    Firsov AA; Portnoy YA; Strukova EN; Shlykova DS; Zinner SH
    Int J Antimicrob Agents; 2014 Oct; 44(4):301-5. PubMed ID: 25218155
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In vitro activities of mutant prevention concentration-targeted concentrations of fluoroquinolones against Staphylococcus aureus in a pharmacodynamic model.
    Allen GP; Kaatz GW; Rybak MJ
    Int J Antimicrob Agents; 2004 Aug; 24(2):150-60. PubMed ID: 15288314
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prevalence of antimicrobial resistance genes in Listeria monocytogenes isolated from dairy farms.
    Srinivasan V; Nam HM; Nguyen LT; Tamilselvam B; Murinda SE; Oliver SP
    Foodborne Pathog Dis; 2005; 2(3):201-11. PubMed ID: 16156701
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Application of pharmacokinetics and pharmacodynamics to antimicrobial therapy of respiratory tract infections.
    Andes D; Anon J; Jacobs MR; Craig WA
    Clin Lab Med; 2004 Jun; 24(2):477-502. PubMed ID: 15177850
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical limitations of in vitro testing of microorganism susceptibility.
    Nightingale J
    Am J Hosp Pharm; 1987 Jan; 44(1):131-7. PubMed ID: 3826085
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In vitro activity of ceftaroline (PPI-0903M, T-91825) against bacteria with defined resistance mechanisms and phenotypes.
    Mushtaq S; Warner M; Ge Y; Kaniga K; Livermore DM
    J Antimicrob Chemother; 2007 Aug; 60(2):300-11. PubMed ID: 17548456
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Therapeutic options in an era of decreasing antimicrobial susceptibility.
    Drlica K; Schmitz FJ
    J Chemother; 2002 Feb; 14 Suppl 2():5-12. PubMed ID: 12003139
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetic/pharmacodynamic model-based combination therapy approach to target antibiotic resistant populations emerged from ciprofloxacin exposure.
    Wu B; Derendorf H
    Pharmazie; 2010 Jun; 65(6):417-20. PubMed ID: 20614689
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetic/pharmacodynamic relationships of antimicrobial drugs used in veterinary medicine.
    McKellar QA; Sanchez Bruni SF; Jones DG
    J Vet Pharmacol Ther; 2004 Dec; 27(6):503-14. PubMed ID: 15601444
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [The implementation of the broth microdilution method to determine bacterial susceptibility to antimicrobial agents].
    Rocksin A; Gerlach GF; Schwarz S
    Berl Munch Tierarztl Wochenschr; 2007; 120(1-2):42-9. PubMed ID: 17290942
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mutant prevention concentrations of pradofloxacin for susceptible and mutant strains of Escherichia coli with reduced fluoroquinolone susceptibility.
    Marcusson LL; Komp Lindgren P; Olofsson SK; Hughes D; Cars O
    Int J Antimicrob Agents; 2014 Oct; 44(4):354-7. PubMed ID: 25129317
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In vitro prevention of the emergence of daptomycin resistance in Staphylococcus aureus and enterococci following combination with amoxicillin/clavulanic acid or ampicillin.
    Entenza JM; Giddey M; Vouillamoz J; Moreillon P
    Int J Antimicrob Agents; 2010 May; 35(5):451-6. PubMed ID: 20185277
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.